NEW DELHI : Bharat Biotech International Ltd will use the adjuvant Alhydroxiquim-II to stimulate the immune response and provide longer-lasting immunity for its new coronavirus candidate vaccine, Covaxin, the company said in a statement Monday. The adjuvant is used under a license agreement signed with ViroVax LLC, based in the …
Read More »